

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant:** Ken Shortman, et al.

**Examiner:** Scott Long

**Serial No.:** 10/584,180

**Art Unit:** 1633

**Filed:** June 23, 2006

**Docket:** 19975

**For:** THERAPEUTIC AGENTS AND  
USES THEREOF

**Dated:** March 15, 2010

**Confirmation No.:** 4755

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Maliszewski C., "Dendritic cells in models of tumor immunity. Role of Flt3 ligand", *Pathol Biol* 49: 481-483 (2001);
2. Morel P. A. et al., "Immunobiology of DC in NOD mice", *J. Leukoc. Biol.* 66: 276-280 (1999);

---

**CERTIFICATE OF ELECTRONIC FILING**

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website on the date shown below.

Dated: March 15, 2010

  
Xiaochun Zhu

3. U.S. Patent Application Publication No. US 2003/0113341 A1, publication date June 19, 2003 to Lynch et al.;
4. McNeil D. G. et al., "Pilot Study of an HLA-A2 Peptide Vaccine Using Flt3 Ligand as a Systemic Vaccine Adjuvant", *Journal of Clinical Immunology* 23(1): 62-72 (2003);
5. Dong J. et al., "Flt-3 Ligand A Potent Dendritic Cell Stimulator and Novel Antitumor Agent", *Cancer Biology & Therapy* 1(5): 486-489 (2002);
6. Rini B. I. et al., "Flt-3 Ligand and Sequential FL/Interleukin-2 in Patients With Metastatic Renal Carcinoma: Clinical and Biologic Activity", *Journal of Immunotherapy* 25(3): 269-277 (2002);
7. PCT International Publication No. WO 02/100317 A2, published December 19, 2002;
8. PCT International Publication No. WO 02/067760 A2, published September 6, 2002;
9. Maraskovsky E. et al., "Dramatic Numerical Increase Of Functionally Mature Dendritic Cells In Flt3 Ligand-Treated Mice", *Dendritic Cells in Fundamental and Clinical Immunology* 33-40 (1997);
10. Maraskovsky E. et al., "Dramatic Increase in the Numbers of Functionally Mature Dendritic Cells in Flt3 Ligand-treated Mice: Multiple Dendritic Cell Subpopulations Identified", *J. Exp. Med.* 184: 1953-1962 (1996);
11. Naik S. et al., "CD8 $\alpha$ <sup>+</sup> mouse spleen dendritic cells do not originate from the CD8 $\alpha$ <sup>-</sup> dendritic cell subset", *Blood* 102(2): 601-604 (2003); and
12. International Search Report, dated March 16, 2006 issued in respect to corresponding International PCT Application No. PCT/AU2004/001840.


Reference numbers 1-8 were cited in an International Search Report dated March 16, 2005 received from the Australian Patent Office. A copy of the Search Report was previously submitted by Applicants on June 23, 2006. The relevance of reference numbers 1-8 has been described in the Search Report.

Applicants are submitting copies of reference numbers 1-2 and 4-11 required by 37 C.F.R. § 1.98 (a)(2)(i) and (ii).

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present application as defined under 37 C.F.R. §1.56.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(c), the Commissioner is hereby authorized to charge the fee in the amount of \$180.00 associated with this communication or credit any overpayment to Deposit Account No. 19-1013/SSMP.

Respectfully submitted,



Xiaochun Zhu  
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza - Suite 300  
Garden City, New York 11530  
(516) 742-4343  
XZ:ab